Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
April 10, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
April 10, 2024 07:02 ET
|
Ocugen
MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
April 10, 2024 07:01 ET
|
HOOKIPA Pharma Inc.
HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumabHB-200 program receives Priority Medicines (PRIME) designation from EMA NEW YORK...
Colliers adds market leader in Philadelphia
April 10, 2024 07:00 ET
|
Colliers International Group Inc
TORONTO and PHILADELPHIA, April 10, 2024 (GLOBE NEWSWIRE) -- Leading diversified professional services and investment management firm Colliers (NASDAQ and TSX: CIGI) today announced the acquisition...
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 10, 2024 07:00 ET
|
Apollomics Inc.
FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat...
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
April 10, 2024 07:00 ET
|
BioXcel Therapeutics
Company plans to initiate trial following recent meeting with FDA No FDA-approved therapies for acute treatment of AAD are currently available NEW HAVEN, Conn., April 10, 2024 (GLOBE NEWSWIRE) --...
L3Harris Selects Mercury to Provide Solid-State Data Recorders for SDA’s Tranche 2 Tracking Layer Satellites
April 10, 2024 07:00 ET
|
Mercury Systems Inc
ANDOVER, Mass., April 10, 2024 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a technology company that delivers mission-critical processing power to the edge, today...
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
April 10, 2024 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
April 10, 2024 07:00 ET
|
Nurix Therapeutics, Inc.
Extended the Strategic Collaboration with Gilead Sciences Extended the Strategic Collaboration with Sanofi to Develop Novel Orally Available Targeted Protein Degrader of STAT6 Presented new case...
Interactive Strength Inc. (Nasdaq: TRNR) to Exhibit CLMBR at FIBO Global Fitness, the World's Largest Trade Show for Fitness, Wellness and Health on April 11-14
April 10, 2024 07:00 ET
|
Interactive Strength Inc.
FIBO Global Fitness Expects to Have More Than 150,000 Visitors for the Trade Show in Cologne, GermanyCLMBR is Receiving Significant Interest From International Boutique Fitness Operators and Gym...